uniQure N.V. (0EE0.L) LSE
26.70
-1.21(-4.34%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
uniQure N.V.
Address
Paasheuvelweg 25a
Amsterdam, 1105 BP
United States of America (the)
Phone
31 20 240 6000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
209
First IPO Date
January 29, 2018
Key Executives
| Name | Title | Pay | Year Born |
| Matthew Craig Kapusta | Chief Executive Officer & Executive Director | 1.05M | 1972 |
| Jeannette Potts | Chief Legal & Compliance Officer and Corporate Secretary | 712,827 | 1962 |
| Richard Porter | Chief Business & Scientific Officer | 732,169 | 1968 |
| Christian Klemt | Chief Financial Officer, Principal Financial Officer & GM of Amsterdam Site | 759,950 | 1973 |
| Walid Abi-Saab | Chief Medical Officer | 945,278 | 1965 |
| Chiara Elizabeth Russo | Senior Director of Investor Relations | 0 | N/A |
| Erin Boyer | Chief People & Culture Officer | 0 | N/A |
| Kylie O'Keefe | Chief Customer & Strategy Officer | 0 | 1985 |
| Tamara Tugal | Business Development Director | 0 | N/A |
| Amin Abujoub | Chief Technical Operations Officer | 0 | N/A |
| Hugo Katus | Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | 0 | N/A |
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
